Nephros (NEPH) Stock Price, News & Analysis

Company Overview

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Key Stats

• Today's Range: $3.75 to $4.13
• 50-Day Range: $2.89 to $5.00
• 52-Week Range: $1.36 to $5.00
• Volume: 28,546 shs
• Average Volume: 42,111 shs
• Market Capitalization: $42.40 million
• P/E Ratio: 33.33
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

Nephros Stock Analysis - MarketRank™

Nephros scored higher than 48% of companies evaluated by MarketBeat, and ranked 614th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nephros has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nephros is 33.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nephros is 33.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.29.

Price to Book Value per Share Ratio

Nephros has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.05% of the float of Nephros has been sold short.

Short Interest Ratio / Days to Cover

Nephros has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nephros has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nephros does not currently pay a dividend.

Dividend Growth

Nephros does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.05% of the float of Nephros has been sold short.

Short Interest Ratio / Days to Cover

Nephros has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nephros has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.07

News Sentiment

Nephros has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Nephros this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for NEPH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Nephros to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nephros insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.70% of the stock of Nephros is held by insiders.

Percentage Held by Institutions

41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NEPH Stock Analysis - Frequently Asked Questions

How have NEPH shares performed this year?

Nephros' stock was trading at $1.47 on January 1st, 2025. Since then, NEPH shares have increased by 172.1% and is now trading at $4.00.

How were Nephros' earnings last quarter?

Nephros Inc. (NASDAQ:NEPH) announced its quarterly earnings results on Thursday, August, 7th. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.05. The firm had revenue of $4.40 million for the quarter, compared to analyst estimates of $3.60 million. Nephros had a trailing twelve-month return on equity of 14.89% and a net margin of 7.95%.
Read the conference call transcript.

Who are Nephros' major shareholders?

Top institutional investors of Nephros include Geode Capital Management LLC (0.88%). Insiders that own company stock include Arthur H Amron and Robert R Jr Banks.
View institutional ownership trends.

How do I buy shares of Nephros?

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nephros own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NEPH
• CIK: 1196298
• Web: www.nephros.com
• Phone: (201) 343-5202
• Fax: 201-343-5207
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nephros: $5.50
• High Price Target: $6.00
• Low Price Target: $5.00
• Potential Upside/Downside: +35.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.12
• Trailing P/E Ratio: 33.79
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $70 thousand
• Net Margins: 7.95%
• Pretax Margin: 8.10%
• Return on Equity: 14.89%
• Return on Assets: 11.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.41
• Quick Ratio: 4.64

Sales & Book Value

• Annual Sales: $16.68 million
• Price / Sales: 2.58
• Cash Flow: $0.02 per share
• Price / Cash Flow: 212.88
• Book Value: $0.91 per share
• Price / Book: 4.46

Miscellaneous

• Outstanding Shares: 10,601,000
• Free Float: 9,891,000
• Market Cap: $42.99 million
• Optionable: Not Optionable
• Beta: 1.11